肿瘤细胞治疗研究
英文原题：Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.
尽管CAR-T（CAR-T）细胞疗法在血液系统恶性肿瘤中取得了显著成功，但其在实体瘤中的治疗效果仍受多种挑战限制，包括肿瘤浸润不足、T细胞耗竭以及免疫抑制性肿瘤微环境（TME）。
尽管CAR-T（CAR-T）细胞疗法在血液系统恶性肿瘤中取得了显著成功，但其在实体瘤中的治疗效果仍受到若干挑战的限制，包括肿瘤浸润不足、T细胞耗竭以及免疫抑制性肿瘤微环境（TME）。CRISPR/Cas是近年来发展的第三代基因编辑技术，具有操作简便和高效的特点。该技术已在多个领域展现出广泛的应用潜力，并已成为改进CAR-T细胞疗法的有力工具。在本综述中，我们总结了应用CRISPR/Cas基因编辑技术增强CAR-T细胞抗实体瘤活性的最新进展。我们还讨论了当前面临的关键挑战，并系统性地提出了克服这些局限性的潜在策略。
Although chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematological malignancies, its therapeutic efficacy in solid tumors remains limited by several challenges, including insufficient tumor infiltration, T cell exhaustion and the immunosuppressive tumor microenvironment (TME). CRISPR/Cas, a third-generation gene editing technology developed in recent years, is characterized by its simplicity and high efficiency. This technology has demonstrated broad application potential across multiple fields and has emerged as a powerful tool for improving CAR-T cell therapy. In this review, we summarize recent advances in the application of CRISPR/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors. We also discuss the key challenges currently faced and systematically propose potential strategies for overcoming the limitations.
MEMBER ACCOUNT
登录成功会直接打开下一页。
